Shenguan Holdings (Group) Limited

Shenguan Holdings (Group) Limited

0.40
USD
-0.04
(-10.04%)
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.95
8.45
6.42
6.02
6.18
5.52
6.18
5.95
7.23
6.39
6.87
6.29
6.33
- -
Basic EPS, GAAP
4.64
3.3
1.77
0.95
0.42
0.49
0.47
0.56
0.76
0.15
0.19
0.17
-0.43
- -
Free Cash Flow per Basic Share
1.56
1.42
1.21
1
2.41
1.59
1.79
2.27
0.46
0.19
0.58
-1.45
-0.76
- -
Dividend per Share
2.78
3.01
0.65
0.54
0.53
0.59
0.63
1.1
1
1.03
1.11
0.73
0.73
- -
Book Value per Share
15.91
15.95
17.02
17.33
17.35
17.32
17.16
16.64
16.46
15.63
14.75
14.22
13.17
13.17
Tangible Book Value per Share
15.21
15.21
14.49
15.28
15.58
16.02
16.94
15.96
16.46
15.63
14.75
14.22
13.17
13.17
Basic Weighted Avg Shares
166
166
164
163
163
163
162
162
162
162
162
162
162
162
Sales/Revenue/Turnover
1,654
1,403
1,055
981
1,008
899
998
962
1,168
1,032
1,110
1,017
1,023
- -
Operating Margin (%)
53.96
48.34
33.71
12.37
5.09
14.06
3.83
7.61
11.8
-1.79
-0.39
2.28
-4.77
- -
Depreciation Expense
75
93
115
150
152
149
150
139
100
101
101
84
77
- -
Net Income, GAAP
771
547
291
154
69
80
75
91
123
24
31
27
-70
- -
Effective Tax Rate (%)
17.41
19.03
15.29
13.89
13.72
25.92
20.59
19.98
26.37
39.83
56.5
34.54
- -
- -
Profit Margin (%)
46.62
39.02
27.63
15.72
6.82
8.93
7.56
9.44
10.5
2.28
2.81
2.62
-6.82
- -
Working Capital
1,005
1,057
1,150
1,202
1,257
1,254
1,218
1,102
1,111
1,164
1,076
1,031
994
994
LT Debt
- -
- -
- -
- -
- -
- -
- -
2
6
2
1
4
3
3
Total Equity
2,644
2,636
2,870
2,895
2,848
2,814
2,776
2,689
2,656
2,519
2,376
2,293
2,126
2,126
Return on Invested Capital (%)
28.52
17.48
8.77
4.42
1.29
1.95
1.16
2.07
3.1
-0.17
0.46
0.43
- -
- -
Return on Capital (%)
28.77
17.94
9.2
5.71
2.89
3.1
2.97
3.39
4.36
1.02
1.29
1.12
- -
- -
Return on Common Equity (%)
30.92
20.74
10.76
5.5
2.43
2.85
2.71
3.32
4.59
0.91
1.27
1.14
-3.15
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
244
414
403
LT Borrowings
- -
- -
- -
LT Finance Leases
4
6
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
162
162
162
Market Capitalization
- -
775
- -

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,540
1,682
1,613
Cash, Cash Equivalents & STI
504
559
534
Accounts Receivable, Net
120
149
151
Inventories
814
913
836
Total Current Liabilities
508
672
618
Payables & Accruals
- -
- -
- -
ST Debt
244
414
403
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.93%
-4.56%
-7.26%
Free Cash Flow
-20.36%
-66.36%
-47.48%
Net Income, GAAP
-46.09%
-77.88%
-361.67%
Sales/Revenue/Turnover
0.19%
1.92%
0.64%
Total Cash Common Dividend
3.97%
-6.37%
0.75%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,110
2024
- -
- -
1,017
2025
- -
- -
1,023

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.19
2024
- -
- -
0.17
2025
- -
- -
-0.43

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.11
2024
- -
- -
0.73
2025
- -
- -
0.73

Company Description

CEO
Zhou Yaxian
Full Time Employees
2,894
Sector
Consumer non-durables
Industry
Food: meat/fish/dairy
Address
Unit 2902, Sino Plaza, 255-257 Gloucester Road Wuzhou China
IPO Date
Oct 13, 2009
Business
Shenguan Holdings (Group) Limited, an investment holding company incorporated in the Cayman Islands in 1989 and headquartered in Causeway Bay, Hong Kong, principally manufactures and sells collagen-based products worldwide under the Shenguan brand. The Group produces edible collagen sausage casings, including its six high-end series of fried, crispy, fresh, tender, bright and colorful variants that account for about 40% of first-half 2025 sales; collagen food products such as Beef Tendon and Bo Bo Chicken; collagen skincare products; polymer collagen medical biomaterials featuring low endotoxin levels below FDA standards; pharmaceutical products and intermediates; collagen medical devices including dental sponges and bone filling materials advancing through clinical trials and regulatory approvals; fine chemicals for human use; and maternal-infant products. Operations span Mainland China, where over 90% of revenue and non-current assets concentrate primarily in Guangxi; Asia excluding Mainland China; and other regions including Southeast Asia, Europe, South America and the United States, serving leading meat processors with certifications like ISO9001, ISO22000, Halal and US FDA export registration. In recent developments, the Group reported 2025 interim results on 25 August 2025 showing revenue of RMB444 million and a net loss of RMB41 million attributable to owners amid weak consumer demand and higher inventory provisions, while achieving 93% sales growth in non-sausage casing segments particularly polymer collagen medical biomaterials; it intensified intelligent production upgrades, raw material supply diversification and market expansion for new collagen applications; advanced clinical trials for dental collagen sponges and refined approvals for collagen bone filling biomaterials; enhanced production efficiency through equipment standardization and cost controls; earned honors including China's 500 Most Valuable Brands 2025 and retained Guangxi collagen research center status; and accumulated 116 patents with collaborations like Huazhong University of Science and Technology yielding publications and joint innovations. Shenguan Holdings is a subsidiary of Rich Top Future Limited and employs about 3,010 staff focused on high-quality collagen technology originating from China's first edible casing patent over 40 years ago.